Indeed, sustained inflammasome suppression raises concerns about increased infection risk—severe IL−1β blockade can worsen outcomes in septic patients, even though it has demonstrated safety in stable populations treated with agents like anakinra or canakinumab (144, 184). Here, IL1B is linked to infection.